在预后良好的患者单囊胚移植中完全省略激素替代治疗方案的内分泌和超声监测的有效性
这项回顾性队列研究纳入2023年6月至2024年10月在土耳其伊斯坦布尔Bahçeci IVF中心接受激素替代治疗周期单冻融囊胚移植的294例患者,比较无监测组与超声及激素监测组的妊娠结局。结果显示两组持续妊娠率、种植率、流产率均无显著差异,省略监测不是持续妊娠的独立预测因素。结论认为在预后良好患者中省略内分泌和超声监测不损害妊娠结局。
要点
- 无监测组与监测组持续妊娠率分别为46.1%和49.1%(OR 0.88,95%CI 0.52-1.49)。
- 两组妊娠率分别为68.4%和69.7%(OR 0.94,95%CI 0.53-1.65),无显著差异。
- 监测不是持续妊娠的独立预测因素(校正OR 0.85,95%CI 0.49-1.47)。
核心结论
- 在预后良好患者中,激素替代治疗周期冻融胚胎移植省略内分泌和超声监测不损害妊娠结局。
- 该做法可减少患者不适和费用而不影响妊娠结局。
研究设计与样本
- 回顾性队列研究,纳入2023年6月至2024年10月在土耳其伊斯坦布尔Bahçeci IVF中心接受激素替代治疗周期单冻融囊胚移植的294例患者。
- 患者分为无监测组(研究组)和超声及激素监测组(对照组)。
- 研究对象为年龄<37岁、因不明原因不孕、多囊卵巢综合征、轻度男性因素不孕或后两者组合导致原发不孕的女性。
主要发现
- 妊娠率:无监测组68.4% vs 监测组69.7%(OR 0.94,95%CI 0.53-1.65)。
- 种植率:无监测组57.9% vs 监测组62.4%(OR 0.82,95%CI 0.48-1.41)。
- 持续妊娠率:无监测组46.1% vs 监测组49.1%(OR 0.88,95%CI 0.52-1.49)。
- 流产率:无监测组11.8% vs 监测组13.3%(OR 0.87,95%CI 0.39-1.94)。
- 监测不是持续妊娠的独立预测因素(校正OR 0.85,95%CI 0.49-1.47)。
临床怎么用
- 作者认为,在预后良好患者中,激素替代治疗周期冻融胚胎移植省略内分泌和超声监测不损害妊娠结局,可减少患者不适和费用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether omitting endocrine and ultrasound monitoring in hormone replacement therapy (HRT) cycles for frozen embryo transfer (FET) affects pregnancy rates in good-prognosis patients. DESIGN: This retrospective cohort study included 294 patients who underwent single, frozen-thawed blastocyst transfer in HRT cycles between June 2023 and October 2024 at Bahçeci IVF Center in Istanbul, Turkey. Patients were stratified into two groups: study group (no monitoring) and control group (ultrasound and hormonal monitoring). SUBJECTS: Women aged <37 years with primary infertility because of unexplained infertility, polycystic ovary syndrome, mild male factor infertility, or a combination of the last two. EXPOSURE: Hormone replacement therapy endometrial preparation with or without endocrine and ultrasound monitoring. MAIN OUTCOME MEASURES: Ongoing pregnancy rate per embryo transfer. Secondary outcomes included implantation and miscarriage rates. RESULTS: Pregnancy rates were 68.4% (study group) and 69.7% (control group) (Odds ratio [OR]: 0.94, 95% confidence interval [CI]: 0.53-1.65). Implantation rates were 57.9% and 62.4%, respectively (OR: 0.82, 95% CI: 0.48-1.41). Ongoing pregnancy rates were 46.1% and 49.1%, respectively (OR: 0.88, 95% CI: 0.52-1.49). Miscarriage rates were 11.8% and 13.3%, respectively (OR: 0.87, 95% CI: 0.39-1.94). Monitoring was not an independent predictor of ongoing pregnancy (adjusted OR: 0.85, 95% CI: 0.49-1.47). CONCLUSION: Omitting endocrine and ultrasound monitoring in HRT cycles for FET does not impair pregnancy outcomes in good-prognosis patients undergoing autologous frozen-thawed embryo transfer after a freeze-all protocol. This practice minimizes patient discomfort and costs without compromising pregnancy outcomes.
引用
- Asoglu MR, Bozdag G, Ozturk E, et al. Validity of completely omitting endocrine and ultrasound monitoring in hormone replacement therapy protocols for frozen embryo transfer in good-prognosis patients undergoing single blastocyst transfer. Fertil Steril. 2025. PMID: 40553745. doi:10.1016/j.fertnstert.2025.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。